• Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (PubMed=11157491).
  

PubMed=2167671; DOI=10.1016/0006-291x(90)90510-t
Okuno Y., Takahashi T., Suzuki A., Ichiba S., Nakamura K., Hitomi K., Sasaki R., Imura H.
Expression of the erythropoietin receptor on a human myeloma cell line.
Biochem. Biophys. Res. Commun. 170:1128-1134(1990)

PubMed=1720489; DOI=10.1016/0145-2126(91)90110-f
Suzuki A., Takahashi T., Okuno Y., Fukumoto M., Fukui H., Koishihara Y., Ohsugi Y., Ohno Y., Imura H.
Estimation of interleukin 6 production by reverse transcriptase-polymerase chain reaction in four human myeloma cell lines.
Leuk. Res. 15:1043-1050(1991)

PubMed=2072743
Okuno Y., Takahashi T., Suzuki A., Ichiba S., Nakamura K., Fukumoto M., Okada T., Okada H., Imura H.
Establishment and characterization of four myeloma cell lines which are responsive to interleukin-6 for their growth.
Leukemia 5:585-591(1991)

DOI=10.1007/0-306-46877-8_4
Jernberg-Wiklund H., Nilsson K.
Multiple myeloma cell lines.
(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

PubMed=11157491; DOI=10.1182/blood.V97.3.729
Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., Bergsagel P.L.
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Blood 97:729-736(2001)

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011; PMCID=PMC2737184
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
Characterization of MYC translocations in multiple myeloma cell lines.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008)